Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | TYR | P14679 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | KDM5A | P29375 | 1/20 | 0.33 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.33 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.32 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.32 |
| ▸ | GRN | P28799 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL783152 | 0.90 | TYR (0.41) | L3MBTL1TYRHSD17B10CA12CA1 | |
| SCHEMBL780340 | 0.85 | GPR35 (0.38) | L3MBTL1HSD17B10MAPK1CA12CA1 | |
| SCHEMBL8657835 | 0.82 | TYR (0.38) | L3MBTL1TYRHSD17B10MAPK1KDM5A | |
| SCHEMBL8102670 | 0.81 | KDM4E (0.38) | L3MBTL1TYRHSD17B10CA12CA1 | |
| SCHEMBL5889466 | 0.81 | HTT (0.39) | HSD17B10MAPK1KDM4ESORT1 | |
| SCHEMBL22066872 | 0.80 | TYR (0.42) | L3MBTL1TYRHSD17B10MAPK1KDM5A | |
| SCHEMBL781811 | 0.75 | TDP1 (0.45) | HSD17B10CYP2C19ALDH1A1KDM4EHPGD | |
| SCHEMBL5676062 | 0.73 | AR (0.41) | ALDH1A1 | |
| Hydrochloric Acid SCHEMBL7049628 | 0.73 | TDP1 (0.44) | HSD17B10CYP2C19ALDH1A1KDM4EHPGD | |
| SCHEMBL782206 | 0.68 | L3MBTL1 (0.41) | L3MBTL1TYRKDM5AKDM5BCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120071628-A1 | TOPICAL THERAPEUTIC AGENT FOR OPHTHALMIC DISEASES COMPRISING COMPOUND CAPABLE OF BINDING SPECIFICALLY TO DNA SEQUENCE | NIHON UNIVERSITY (JP) | 2012-03-22 | — | — | US | disclosed |
| US-20110046070-A1 | GENE EXPRESSION INHIBITOR SELECTIVE FOR MATRIX METALLOPROTEINASE-9 GENE | NIHON UNIVERSITY (JP) | 2011-02-24 | — | — | US | disclosed |
| US-7888516-B2 | transforming growth factor (TGF- beta ) gene expression inhibitors comprising a pyrrole-imidazole polyamides, used as a therapeutic agent for diseases associated with the production of TGF- beta; drugs; side effect reduction | NIHON UNIVERSITY (JP) | 2011-02-15 | — | — | US | disclosed |
| EP-2266583-A1 | GENE EXPRESSION INHIBITOR SELECTIVE FOR MATRIX METALLOPROTEINASE-9 GENE | Nihon University (JP) | 2010-12-29 | — | — | EP | disclosed |
| US-7807844-B2 | TGF-β gene expression inhibitor | NIHON UNIVERSITY (JP) | 2010-10-05 | — | — | US | disclosed |
| US-20080255368-A1 | Tgf-ß Gene Expression Inhibitor | NIHON UNIVERSITY (JP) | 2008-10-16 | — | — | US | disclosed |
| US-20080103187-A1 | Tgf-Beta Gene Expression Inhibitor | GENTIER BIOSYSTEMS, INC. (JP) | 2008-05-01 | — | — | US | disclosed |
| EP-1779850-A1 | TGF- GENE EXPRESSION INHIBITOR | Nihon University (JP) | 2007-05-02 | — | — | EP | disclosed |
| US-7067622-B2 | Method of the solid phase synthesis of pyrrole-imidazole polyamide | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2006-06-27 | — | — | US | disclosed |
| US-7064218-B2 | Aromatic compounds and poly(oxyalkylene) containing aromatic compounds possessing antibacterial, antifungal or antitumor activity | GENELABS TECHNOLOGIES, INC. (US) | 2006-06-20 | — | — | US | disclosed |
| US-20040171799-A1 | Method of the solid phase synhesis of pyrrole-imidazole polyamide | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2004-09-02 | — | — | US | disclosed |
| US-20030212113-A1 | Novel aromatic compounds and poly(oxyalkylene) containing aromatic compounds possessing antibacterial, antifungal or antitumor activity | GLAXOSMITHKLINE LLC | 2003-11-13 | — | — | US | disclosed |
| WO-2003057212-A1 | POLYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL, ANTIFUNGAL OR ANTITUMOR ACTIVITY | GENELABS TECHNOLOGIES, INC. (US) | 2003-07-17 | — | — | WO | disclosed |
| US-20030119749-A1 | Novel compounds possessing antibacterial, antifungal or antitumor activity | SMITHKLINE BEECHAM CORPORATION | 2003-06-26 | — | — | US | disclosed |
| EP-1294713-A2 | COMPOUNDS POSSESSING ANTIBACTERIAL, ANTIFUNGAL OR ANTITUMOR ACTIVITY | GENELABS TECHNOLOGIES, INC. (US) | 2003-03-26 | — | — | EP | disclosed |
| WO-2002000650-A9 | NOVEL COMPOUNDS POSSESSING ANTIBACTERIAL, ANTIFUNGAL OR ANTITUMOR ACTIVITY | GENELABS TECH INC (US) | 2003-03-06 | — | — | WO | disclosed |
| US-20020037856-A1 | Novel compounds possessing antibacterial, antifungal or antitumor activity | GENELABS TECHNOLOGIES, INC. | 2002-03-28 | — | — | US | disclosed |
| WO-2002000650-A2 | NOVEL COMPOUNDS POSSESSING ANTIBACTERIAL, ANTIFUNGAL OR ANTITUMOR ACTIVITY | GENELABS TECHNOLOGIES, INC. (US) | 2002-01-03 | — | — | WO | disclosed |
| EP-0661260-B1 | New bi-aromatic compounds derived from amides pharmaceutical compositions and cosmetic compositions containing them and their use | CIRD GALDERMA (FR) | 1997-03-12 | — | — | EP | disclosed |
| EP-0661260-A1 | New bi-aromatic compounds derived from amides pharmaceutical compositions and cosmetic compositions containing them and their use | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA, ( CIRD GALDERMA) (FR) | 1995-07-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040171799-A1 | Method of the solid phase synhesis of pyrrole-imidazole polyamide | PCNA, POLH, PNISR | L3MBTL1 2924/4885TYR 2453/4885HSD17B10 4626/4885 |
| US-20120071628-A1 | TOPICAL THERAPEUTIC AGENT FOR OPHTHALMIC DISEASES COMPRISING COMPOUND CAPABLE OF BINDING SPECIFICALLY TO DNA SEQUENCE | POLH, POLB, POLK | L3MBTL1 4494/4885TYR 1487/4885HSD17B10 3576/4885 |
| US-20080255368-A1 | Tgf-ß Gene Expression Inhibitor | GABRP, GABRB2, GABRB1 | L3MBTL1 671/4885TYR 4399/4885HSD17B10 3070/4885 |
| US-20030119749-A1 | Novel compounds possessing antibacterial, antifungal or antitumor activity | CYP51A1, MCL1, ERG28 | L3MBTL1 4293/4885TYR 156/4885HSD17B10 2227/4885 |
| US-20110046070-A1 | GENE EXPRESSION INHIBITOR SELECTIVE FOR MATRIX METALLOPROTEINASE-9 GENE | GABRP, GABRD, MMP9 | L3MBTL1 1217/4885TYR 3009/4885HSD17B10 3459/4885 |
| US-20080103187-A1 | Tgf-Beta Gene Expression Inhibitor | TGFBR1, TGFBR2, SMAD2 | L3MBTL1 285/4885TYR 4290/4885HSD17B10 3330/4885 |
| US-20020037856-A1 | Novel compounds possessing antibacterial, antifungal or antitumor activity | CYP51A1, MCL1, ERG28 | L3MBTL1 4293/4885TYR 156/4885HSD17B10 2227/4885 |
| US-20030212113-A1 | Novel aromatic compounds and poly(oxyalkylene) containing aromatic compounds possessing antibacterial, antifungal or antitumor activity | TYR, CYP51A1, ODC1 | L3MBTL1 4222/4885TYR 1/4885HSD17B10 1184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.